血管紧张素转化酶基因I／D多态性与奥美沙坦酯降压疗效的临床研究

目的：探讨血管紧张素转化酶（ACE）基因I／D多态性与奥美沙坦酯降压疗效的关系。方法：高血压患者服用奥美沙坦酯8周，在观察降压疗效的同时，用PCR—RFLP方法对患者血白细胞基因组DNA多态性位点ACEI／D基因型进行检测；按不同ACE基因型进行分组，比较不同基因型患者的血压下降值、降压总有效率的差异。结果：ACE基因ID＋DD基因型和II基因型患者使用奥美沙坦酯8周后收缩压下降幅度分别为16．23±6．51mmHg（2．164±0．868kPa，1kPa=7．5mmHg）、5．10±8．66mmHg，降压总有效率分别为81．25％、33．34％，组间比较有统计学差异（P〈0．05）；舒张压下降幅度分别为13．34±7．25mmHg、6．21±5．29mmHg，组间比较无统计学差异（P〉0．05）。结论：ACE基因ID＋DD基因型高血压患者对奥美沙坦酯降压治疗较敏感。

Study on Relationship between the Gene Polymorphism of ACE I/D and Efficacy of Olmesartan Medoxomil in the Treatment of Patients with Hypertention

OBJECTIVE： To investigate the relation between angiotensin- converting- enzyme （ACE） I/D gene polymorphism and efficacy of Olmesartan medoxomil in the treatment of patients with hypertention. METHODS： After all the patients had received Olmesartan medoxomil for eight weeks the efficacy were recorded. At the meanwhile the gene polymorphisms of ACE I/D were detected by polymerase chain reaction （ PCR - RFLP）. The patients were divided into different groups by ACE genetype and blood pressure de- gression value and underpressure total effective rate of different genotypic patients were compared. RESULTS： After all the hypertension patients had received Olmesartan medoxomil for eight weeks the systolic pressure value reduction in the patients with ID ＋ DD and II genotypes for ACE gene were 16. 23 ±6. 51mmHg and 5. 10 ± 8.66mmHg respectively, and underpressure total effective rate were 81.25% and 33. 34% respectively. There were statistical difference between this two group （P 〈 0. 05 ）. The diastolic pressure values of reduction in the patients with ID ＋ DD and II genotypes for ACE gene were 13.34 ±7.25mmHg and 6. 21 ±5.29mmHg respectively and there were no statistical difference between the two groups （ P 〈 0. 05 ）. CONCLUSION ： The primary hypertention patients with ACE ID ＋ DD genotype are more susceptible to Olmesartan medoxomil therapy.